BMS 986226
Alternative Names: BMS-986226Latest Information Update: 07 Mar 2023
At a glance
- Originator Bristol-Myers Squibb
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Inducible T-cell co-stimulator protein antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Solid tumours
Most Recent Events
- 28 Feb 2023 Discontinued - Phase-I/II for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Canada (IV) as of February 2023 (Bristol-Myers Squibb pipeline, February 2023) (NCT03251924)
- 28 Feb 2023 Discontinued - Phase-I/II for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Spain (IV) as of February 2023 (Bristol-Myers Squibb pipeline, February 2023) (NCT03251924)
- 28 Feb 2023 Discontinued - Phase-I/II for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease) in Switzerland (IV) as of February 2023 (Bristol-Myers Squibb pipeline, February 2023) (NCT03251924)